Home > Insider Trading > Filing (0001209191-11-051862)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1012140	Onyx Pharmaceuticals Inc	ONXX	Biological Products, (No Disgnostic Substances) (2836)	943154463

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1365619	Laura Brege	C/O Onyx Pharmaceuticals, Inc. 249 East Grand Ave. South San Francisco CA 94080	Evp, Corporate Affairs	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2011-10-14	5,904	$15.44	45,574	No	4	M	Direct
Common Stock	Acquisiton	2011-10-14	4,096	$24.84	49,670	No	4	M	Direct
Common Stock	Disposition	2011-10-14	10,000	$36.01	39,670	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2011-10-14	5,904	$0.00	5,904	$15.44
Common Stock	Stock Option (Right to Buy)	Disposition	2011-10-14	4,096	$0.00	4,096	$24.84

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
36,596		2016-06-12	No	4	M	Direct
65,904		2017-03-30	No	4	M	Direct

Footnotes

Includes 243 shares purchased through the issuer's ESPP during the year.
Shares sold pursuant to a 10b5-1 plan.
Twenty-Five percent of the shares subject to the option become exercisable 1 year from the date of grant and the remainder become exercisable at a rate of 1/48th per month thereafter.
12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.